People with weakened immune systems face a significantly higher risk of developing shingles, and when they do, the disease is more likely to cause severe, potentially life-threatening complications. That’s why the CDC recommends the shingles vaccine (Shingrix) for immunocompromised adults starting at age 19, three decades earlier than the general population threshold of 50. The vaccine is specifically designed to be safe for this group, and it provides meaningful protection even when the immune system isn’t functioning at full strength.
The Risk Is Substantially Higher
Shingles happens when the chickenpox virus, which stays dormant in your nerve cells after your initial infection, reactivates. A healthy immune system keeps the virus in check for decades. When your immune system is suppressed by disease or medication, that control weakens, and the virus is far more likely to flare up.
The numbers reflect this clearly. In a large study tracking over 1.3 million adults aged 50 and older, about 3.4% of those who became immunosuppressed during the study period went on to develop shingles. Among people with blood cancers, the shingles rate reaches as high as 247 per 1,000 person-years, and solid organ cancers see rates around 219 per 1,000 person-years. These figures dwarf the rates in the general population. Shingles also recurs more often in immunocompromised people, with recurrence rates around 9 per 1,000 person-years in adults over 50.
Complications Are More Severe
For most healthy adults, shingles means a painful rash that clears up in a few weeks. For someone with a weakened immune system, the virus can escape the single nerve cluster where it typically stays contained and spread throughout the body. This is called disseminated shingles, and it’s dramatically more common in immunocompromised patients. While fewer than 1% of healthy people experience dissemination, the rate climbs to 10–15% in stem cell transplant recipients, up to nearly 15% in solid organ transplant recipients, and as high as 19% in people with blood cancers.
When the virus disseminates, it can attack organs and blood vessels, causing inflammation of the retina (which can lead to vision loss), inflammation of the brain, blood vessel damage that raises stroke risk, partial facial paralysis, and nerve palsies. Solid organ transplant recipients are especially vulnerable to nerve palsies, with rates roughly 23 times higher than in the general population. Stroke risk increases after any shingles episode but is particularly elevated when the eyes are involved or when the patient is immunocompromised.
Up to 18% of all people who get shingles develop postherpetic neuralgia, a condition where burning or stabbing nerve pain persists for months or even years after the rash heals. Immunocompromised individuals develop postherpetic neuralgia at higher rates than the general population, with the highest incidence among people who have had blood or stem cell transplants. This chronic pain can severely limit daily functioning and quality of life.
The Vaccine Works Differently Than the Old One
The older shingles vaccine (Zostavax) used a weakened but live form of the virus, which made it unsafe for people with compromised immune systems. A live virus, even an attenuated one, can cause the very disease it’s meant to prevent when the immune system can’t keep it in check.
Shingrix works on an entirely different principle. It contains a single protein from the surface of the virus, combined with an ingredient that boosts the immune response. There is no live virus in the vaccine, so it cannot cause shingles. This is what makes it safe for people on chemotherapy, immunosuppressive drugs, or those living with conditions like HIV. If you previously received the older live vaccine, you can still get Shingrix.
How Well It Protects
Shingrix is less effective in immunocompromised people than in healthy adults, but it still provides substantial protection. Across immunocompromised populations overall, the vaccine is about 60% effective at preventing shingles. In people with blood cancers specifically, efficacy reaches 87%. For stem cell transplant recipients, it’s about 68%. Compared to being unvaccinated, real-world data shows the vaccine reduces shingles risk by roughly 65% in immunocompromised adults.
These numbers are lower than the 90%+ efficacy seen in healthy older adults, and that’s expected. A weakened immune system mounts a smaller response to any vaccine. But given how much more dangerous shingles is for this population, even 60–68% protection represents a meaningful reduction in the chance of a severe, potentially disabling illness.
Who Qualifies and When to Get It
The FDA approved Shingrix for immunocompromised adults starting at age 18. The CDC’s vaccine advisory committee specifically recommends it for adults 19 and older who fall into any of these categories:
- Stem cell or bone marrow transplant recipients
- Solid organ transplant recipients
- People being treated for cancer (including chemotherapy, radiation, or surgical removal of the spleen)
- People living with HIV
- People with autoimmune or inflammatory conditions who take medications that suppress immune function
The vaccine is given as two shots. Timing matters, especially if you’re about to start treatment that will suppress your immune system. The CDC recommends getting vaccinated before beginning chemotherapy, immunosuppressive medications, or radiation therapy when possible, since your body will mount a stronger immune response while your defenses are still intact. If you’re on a medication that targets specific immune cells (like rituximab), the ideal window is about four weeks before your next scheduled dose.
If you’re already on immunosuppressive treatment, you can still receive the vaccine. The protection may be somewhat reduced, but vaccination during treatment is still considered beneficial and safe. There’s no need to wait until treatment ends, particularly for people on long-term immunosuppression who may never have a treatment-free window.
Side Effects to Expect
Shingrix is known for causing a noticeable reaction in many people, regardless of immune status. Soreness at the injection site, fatigue, muscle aches, and headache are common and typically resolve within two to three days. Some people feel wiped out for a day or two after the shot. These reactions are a sign that your immune system is responding to the vaccine, and they are not dangerous. The side effect profile in immunocompromised patients is generally similar to what’s seen in healthy adults.